SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|Date of Report (Date of Earliest Event Reported):||February 10, 2005|
LAIDLAW INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|of incorporation)||File Number)||Identification No.)|
|55 Shuman Blvd. Suite 400, Naperville, Illinois||60563|
(Address of principal executive offices)
|Registrants telephone number, including area code:||(630) 848-3000|
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On February 10, 2005, Laidlaw International, Inc. issued a press release announcing the completion of the sale of its healthcare companies. Pro forma financial statements reflecting the sale of the healthcare companies will be issued in a Form 8K within four business days.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|LAIDLAW INTERNATIONAL, INC.|
|February 10, 2005||By:||
Jeffrey W. Sanders
|Name: Jeffrey W. Sanders|
|Title: Vice President, Corporate Development and Controller|
|Press Release dated February 10, 2005|